Total Payments
$872,312
2024 Payments
$135,310
Companies
48
Transactions
553
Medicare Patients
458
Medicare Billing
$92,042
Payment Breakdown by Category
Consulting$445,204 (51.0%)
Travel$187,756 (21.5%)
Other$116,555 (13.4%)
Research$111,641 (12.8%)
Food & Beverage$10,000 (1.1%)
Education$1,157 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $445,204 | 167 | 51.0% |
| Travel and Lodging | $187,756 | 120 | 21.5% |
| Unspecified | $111,641 | 53 | 12.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $101,965 | 20 | 11.7% |
| Honoraria | $14,590 | 6 | 1.7% |
| Food and Beverage | $10,000 | 182 | 1.1% |
| Education | $1,157 | 5 | 0.1% |
Payments by Type
General
$760,671
500 transactions
Research
$111,641
53 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $107,395 | 43 | $0 (2024) |
| Eli Lilly and Company | $92,407 | 5 | $0 (2024) |
| AstraZeneca UK Limited | $74,044 | 45 | $0 (2023) |
| Merck Sharp & Dohme LLC | $73,037 | 44 | $0 (2024) |
| F. Hoffmann-La Roche AG | $69,113 | 33 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $50,021 | 5 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $46,636 | 45 | $0 (2024) |
| Eisai Inc. | $38,187 | 34 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $36,178 | 43 | $0 (2024) |
| Daiichi Sankyo Inc. | $28,381 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $135,310 | 74 | Daiichi Sankyo Inc. ($20,632) |
| 2023 | $146,198 | 67 | SANOFI-AVENTIS U.S. LLC ($50,021) |
| 2022 | $105,376 | 65 | GlaxoSmithKline, LLC. ($25,648) |
| 2021 | $93,052 | 48 | GlaxoSmithKline, LLC. ($30,214) |
| 2020 | $76,905 | 49 | GlaxoSmithKline, LLC. ($24,147) |
| 2019 | $95,597 | 89 | AstraZeneca Pharmaceuticals LP ($18,612) |
| 2018 | $144,974 | 76 | Eli Lilly and Company ($89,757) |
| 2017 | $74,901 | 85 | F. Hoffmann-La Roche AG ($28,244) |
All Payment Transactions
553 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2024 | Genmab U.S., Inc. | — | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| 12/14/2024 | Genmab U.S., Inc. | — | Food and Beverage | Cash or cash equivalent | $56.79 | General |
| 12/13/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $622.21 | General |
| 12/12/2024 | Genmab U.S., Inc. | — | Travel and Lodging | Cash or cash equivalent | $13,082.77 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $14,400.00 | General |
| 12/03/2024 | BioNTech SE | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 11/27/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $620.00 | General |
| 11/20/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 11/20/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,490.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $45.98 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $772.57 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $288.33 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $247.47 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $208.75 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $95.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $48.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $45.98 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $247.47 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $20.47 | General |
| 10/19/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $7.86 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B TRIAL OF LY2606368 IN COMBINATION WITH CISPLATIN OR CETUXIMAB IN ADVANCED AND-OR METASTATIC TUMORS | Eli Lilly and Company | $82,857 | 1 |
| A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER | Regeneron Pharmaceuticals, Inc. | $13,961 | 17 |
| FEASIBILITY IB TRIAL OF PACLITAXEL CARBOPLATIN GALUNISERTIB A SMALL MOLECULE INHIBITOR OF THE KINASE DOMAIN OF TYPE 1 TGF-B RECEPTOR IN PATIENTS WITH NEWLY DIAGNOSED, PERSISTENT OR RECURRENT CARCINOSARCOMA OF THE UTERUS OR OVARY | Eli Lilly and Company | $5,990 | 1 |
| A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER | F. Hoffmann-La Roche AG | $2,310 | 7 |
| A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | TESARO, Inc. | $2,148 | 16 |
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $1,956 | 2 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 1B-2 STUDY OF LY2228820 A P38 MAPK INHIBITOR PLUS GEMCITABINE AND CARBOPLATIN VERSUS GEMCITABINE AND CARBOPLATIN FOR WOMEN WITH PLATINUM-SENSITIVE OVARIAN CANCER | Eli Lilly and Company | $910.00 | 1 |
| Libtayo Clinical Publication Program | Regeneron Pharmaceuticals, Inc. | $491.25 | 5 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $392.00 | 1 |
| A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | F. Hoffmann-La Roche AG | $369.38 | 1 |
| REGN3767 Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $256.81 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 69 | 133 | $62,540 | $13,143 |
| 2022 | 4 | 103 | 195 | $66,643 | $14,481 |
| 2021 | 5 | 117 | 258 | $53,783 | $26,195 |
| 2020 | 7 | 169 | 373 | $77,518 | $38,223 |
Total Patients
458
Total Services
959
Medicare Billing
$92,042
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 93 | $47,535 | $10,233 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 32 | 40 | $15,005 | $2,910 | 19.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 61 | $29,259 | $6,594 | 22.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 32 | 69 | $16,021 | $3,616 | 22.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 47 | $16,882 | $3,398 | 20.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 18 | $4,481 | $872.70 | 19.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 16 | 81 | $13,440 | $12,960 | 96.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 42 | 70 | $16,141 | $5,295 | 32.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 22 | 36 | $13,028 | $4,068 | 31.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 26 | 60 | $9,420 | $3,300 | 35.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 11 | 11 | $1,754 | $572.00 | 32.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 18 | 110 | $17,600 | $17,482 | 99.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 57 | 111 | $24,975 | $8,379 | 33.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 29 | 68 | $14,960 | $5,581 | 37.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 16 | 20 | $6,860 | $2,022 | 29.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $5,136 | $1,921 | 37.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 21 | 31 | $4,753 | $1,640 | 34.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 16 | 21 | $3,234 | $1,198 | 37.1% |
About Dr. Kathleen Moore, MD
Dr. Kathleen Moore, MD is a Obstetrics & Gynecology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871680249.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kathleen Moore, MD has received a total of $872,312 in payments from pharmaceutical and medical device companies, with $135,310 received in 2024. These payments were reported across 553 transactions from 48 companies. The most common payment nature is "Consulting Fee" ($445,204).
As a Medicare-enrolled provider, Moore has provided services to 458 Medicare beneficiaries, totaling 959 services with total Medicare billing of $92,042. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Location Oklahoma City, OK
- Active Since 10/06/2006
- Last Updated 01/14/2011
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1871680249
Products in Payments
- LYNPARZA (Drug) $67,302
- LIBTAYO (Biological) $65,242
- ZEJULA (Drug) $64,252
- Avastin (Biological) $47,067
- Lenvima (Drug) $35,742
- TECENTRIQ (Biological) $25,977
- ELAHERE (Drug) $15,635
- Rubraca (Drug) $10,181
- Korlym (Drug) $7,899
- YONDELIS (Drug) $6,711
- Venclexta (Drug) $6,621
- FYARRO (Drug) $6,282
- BAVENCIO (Drug) $6,000
- Enhertu (Drug) $5,823
- Fyarro (Drug) $5,320
- Non-Product Specific (Device) $4,620
- Elahere (Biological) $3,262
- MYCHOICE CDX (Device) $3,000
- BENCHMARK SPECIAL STAINS WASH II (Device) $2,900
- KIMMTRAK (Drug) $2,885
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Oklahoma City
Tori O'daniel, Md, MD
Obstetrics & Gynecology — Payments: $596,012
Obstetrics & Gynecology $596,012
Lieschen Quiroz, M.d, M.D
Obstetrics & Gynecology — Payments: $41,813
Obstetrics & Gynecology $41,813
Benjamin Barenberg, M.d, M.D
Obstetrics & Gynecology — Payments: $40,741
Obstetrics & Gynecology $40,741
Beverly Vavricka, Md, MD
Obstetrics & Gynecology — Payments: $26,266
Obstetrics & Gynecology $26,266
Catherine Hildebrand, Md, MD
Obstetrics & Gynecology — Payments: $12,587
Obstetrics & Gynecology $12,587
Monica Reid, Md, MD
Obstetrics & Gynecology — Payments: $12,543
Obstetrics & Gynecology $12,543